692 related articles for article (PubMed ID: 9412874)
1. [Comparative antimicrobial activity of RP 59,500 (quinupristin-dalfopristin), the first semisynthetic injectable streptgramin, against gram-positive cocci and other recent clinical pathogens].
Nakashio S; Iwasawa H; Iino S; Shimada J
Jpn J Antibiot; 1997 Oct; 50(10):844-53. PubMed ID: 9412874
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of antimicrobial and bactericidal activities and postantibiotic effects of macrolides antibiotics against clinical isolates, and examination of shape alteration by scanning electron microscope].
Yano H; Kobayashi T; Okitsu N; Aoki A; Toriya M; Nakada Y; Sagai H; Iyobe S; Inoue M
Jpn J Antibiot; 2007 Feb; 60(1):31-46. PubMed ID: 17436861
[TBL] [Abstract][Full Text] [Related]
3. [Antimicrobial activities of macrolides against recent clinical isolates, and analysis of resistant mechanisms].
Okubo T; Iyobe S; Fujiki Y; Sagai H
Jpn J Antibiot; 2003 Jun; 56(3):163-70. PubMed ID: 12942787
[TBL] [Abstract][Full Text] [Related]
4. [Antimicrobial activities of roxithromycin against recently obtained clinical isolates].
Igari J; Oguri T; Tachibana Y; Misawa N; Nakamura A; Shitara M; Umezu S; Nakamura Y; Tazawa S; Shimoura M; Ugajin K; Mori T; Shimada J; Kaku M; Murase M; Hirakata Y; Matsuda J
Jpn J Antibiot; 1997 Jul; 50(7):640-9. PubMed ID: 9743909
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
7. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
9. In vitro antimicrobial activity and MIC quality control guidelines of RPR 106972 (RPR 112808/RPR106950): a novel orally administered streptogramin combination. The Quality Control Study Group.
Putnam SD; Jones RN; Johnson DM
Diagn Microbiol Infect Dis; 1997 Jul; 28(3):139-47. PubMed ID: 9294704
[TBL] [Abstract][Full Text] [Related]
10. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
11. [Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2006].
Yamaguchi T; Yoshida I; Itoh Y; Tachibana M; Takahashi C; Kaku M; Kanemitsu K; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Baba H; Matsuo S; Asari S; Toyokawa M; Matsuoka K; Kusano N; Nose M; Murase M; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
Jpn J Antibiot; 2010 Dec; 63(6):431-56. PubMed ID: 21425596
[TBL] [Abstract][Full Text] [Related]
12. [Antibiotic resistance of Gram-positive cocci isolated in 2008].
Dorobăţ OM; Bădicuţ I; Tălăpan D; Tenea C; Rafila A
Bacteriol Virusol Parazitol Epidemiol; 2010; 55(2):83-92. PubMed ID: 21553473
[TBL] [Abstract][Full Text] [Related]
13. [Surveillance on gram-positive bacteria isolated from patients with hospital acquired infections or community acquired infections].
Li JT; Li Y; Wang J;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):365-74. PubMed ID: 12820911
[TBL] [Abstract][Full Text] [Related]
14. In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus.
Kang SL; Rybak MJ
J Antimicrob Chemother; 1997 May; 39 Suppl A():33-9. PubMed ID: 9511060
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid at 30:70 ratio) compared to alternative ratios for in vitro testing.
Jamjian C; Barrett MS; Jones RN
Diagn Microbiol Infect Dis; 1997 Apr; 27(4):129-38. PubMed ID: 9154409
[TBL] [Abstract][Full Text] [Related]
17. [Antimicrobial activity of clarithromycin and its effect on bacterial adherence to medical material].
Nakashio S; Susa C; Qiu S; Kijima A; Iwasawa H; Shimomura H; Kanemitsu K; Hori S; Mizushima Y; Shimada J
Jpn J Antibiot; 1993 Jun; 46(6):428-36. PubMed ID: 8360978
[TBL] [Abstract][Full Text] [Related]
18. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
Bouanchaud DH
J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
[TBL] [Abstract][Full Text] [Related]
19. [Antimicrobial susceptibility of clinical isolates of aerobic gram-positive cocci and anaerobic bacteria in 2008].
Yoshida I; Yamaguchi T; Kudo R; Fuji R; Takahashi C; Oota R; Kaku M; Kunishima H; Okada M; Horikawa Y; Shiotani J; Kino H; Ono Y; Fujita S; Matsuo S; Kono H; Asari S; Toyokawa M; Kusano N; Nose M; Horii T; Tanimoto A; Miyamoto H; Saikawa T; Hiramatsu K; Kohno S; Yanagihara K; Yamane N; Nakasone I; Maki H; Yamano Y
Jpn J Antibiot; 2012 Feb; 65(1):49-72. PubMed ID: 22808693
[TBL] [Abstract][Full Text] [Related]
20. In vitro postantibiotic effect of roxithromycin and erythromycin against gram-positive cocci.
Chang JC; Hsueh PR; Young C
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1992 Nov; 25(4):276-84. PubMed ID: 1342645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
